{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:32:37Z","timestamp":1793914357537,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijantimicag.2018.07.012","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T03:32:07Z","timestamp":1532403127000},"page":"608-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro activity of oritavancin in combination with rifampin or gentamicin against prosthetic joint infection-associated methicillin-resistant Staphylococcus epidermidis biofilms"],"prefix":"10.1016","volume":"52","author":[{"given":"Qun","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Karau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash S.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0001","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jhin.2017.11.008","article-title":"Staphylococcus aureus and Staphylococcus epidermidis infections on implants","volume":"98","author":"Oliveira","year":"2018","journal-title":"J Hosp Infec"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0003","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.arth.2007.10.017","article-title":"Infection burden for hip and knee arthroplasty in the United States","volume":"23","author":"Kurtz","year":"2008","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.VMBF-0022-2015","article-title":"The staphylococcal biofilm: adhesins, regulation, and host response","volume":"4","author":"Paharik","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1874285801711010053","article-title":"Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents","volume":"11","author":"Singh","year":"2017","journal-title":"Open Microbiol J"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0006","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.00952-09","article-title":"Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates","volume":"53","author":"Arhin","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2016.07.025","article-title":"Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013\u20132014)","volume":"86","author":"Duncan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0008","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.diagmicrobio.2017.01.006","article-title":"In vitro activity of oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015","volume":"87","author":"Karlowsky","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2018.07.012_bib0009","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0010","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0011","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0012","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1128\/AAC.02932-14","article-title":"Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents","volume":"58","author":"Lin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0013","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.07.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02001-17","article-title":"Evaluation of non-tissue culture- versus tissue culture-treated microplates for oritavancin susceptibility testing","volume":"56","author":"Yan","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.07.012_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2018.05.010","article-title":"In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection","volume":"92","author":"Yan","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0016","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 11th ed. CLSI document M07. CLSI 2018, Wayne, PA: Clinical and Laboratory Standards Institute."},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0017","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms","volume":"37","author":"Ceri","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2014.03.015","article-title":"In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene","volume":"44","author":"Arhin","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0019","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/jac\/dkw588","article-title":"Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis","volume":"72","author":"Werth","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0020","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/jac\/dkw447","article-title":"In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus","volume":"72","author":"Ruppen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0021","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/AAC.02764-13","article-title":"A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus","volume":"58","author":"Barber","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0022","unstructured":"Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. CLSI 2018, Wayne, PA: Clinical and Laboratory Standards Institute."},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0023","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2018 European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters, v8.0, http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf."},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0024","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10096-010-0952-9","article-title":"Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention","volume":"29","author":"El Helou","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.07.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01644-16","article-title":"Activity of tedizolid in methicillin-resistant Staphylococcus epidermidis experimental foreign body-associated osteomyelitis","volume":"61","author":"Park","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0027","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12223-013-0296-9","article-title":"Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm","volume":"59","author":"Szczuka","year":"2014","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0028","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijantimicag.2014.11.011","article-title":"Inefficacy of vancomycin and teicoplanin in eradicating and killing Staphylococcus epidermidis biofilms in vitro","volume":"45","author":"Claessens","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0029","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Parra-Ruiz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0030","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1128\/AAC.00134-09","article-title":"Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis","volume":"53","author":"LaPlante","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky087","article-title":"Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms","author":"Dall","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0032","series-title":"47th Intersci. Conf. Antimicrob. Agents Chemother.","article-title":"Mechanisms of action of oritavancin in Staphylococcus aureus","author":"Arhin","year":"2007"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0033","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/dkn513","article-title":"Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus","volume":"63","author":"Rose","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0034","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01822-16","article-title":"Rifampin-based combination therapy is active in foreign-body osteomyelitis after prior rifampin monotherapy","volume":"61","author":"Brinkman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.012_bib0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T14:48:01Z","timestamp":1604674081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918302036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0924857918302036"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of oritavancin in combination with rifampin or gentamicin against prosthetic joint infection-associated methicillin-resistant Staphylococcus epidermidis biofilms","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}